ULTIMATE FAMILY MEDICINE BOARD
REVIEW 2026 COMPREHENSIVE STUDY
GUIDE & PRACTICE TEST PACK
Master the 2026 Family Medicine Certification Examination with
this comprehensive, high-yield board review simulation optimized
for peak clinical performance. Each question features realistic
clinical vignettes spanning pediatric, geriatric, and chronic disease
management, meticulously formatted with italicized correct
answers and bold-italicized rationales for immediate self-grading.
This expert-curated test prep guide is the ultimate resource for
residents and physicians aiming to pass the ABFM and AAFP
board exams on their first attempt.
Section 1: Chronic Disease Management
Question 1
A 62-year-old man with type 2 diabetes mellitus,
hypertension, and stage 3a chronic kidney disease
(eGFR 48 mL/min/1.73m²) comes for follow-up. His
current medications include maximum-dose
metformin and lisinopril, but his HbA1c is 8.1%.
Aside from glycemic control, which class of
medication should be added to provide proven renal
and cardiovascular protective benefits?
A) Sulfonylurea
B) Dipeptidyl peptidase-4 (DPP-4) inhibitor
C) Sodium-glucose cotransporter-2 (SGLT2)
inhibitor
,D) Long-acting basal insulin
Rationale: SGLT2 inhibitors (such as
empagliflozin or dapagliflozin) have robust,
guideline-backed evidence demonstrating a
reduction in the progression of diabetic kidney
disease, cardiovascular events, and heart failure
hospitalizations, even in patients already
optimized on metformin.
Question 2
A 54-year-old African American woman with
essential hypertension presents with blood pressure
readings consistently averaging 152/94 mmHg over
three separate visits. She currently takes no
medications. According to current ACC/AHA
guidelines, what is the most appropriate initial
pharmacological treatment regimen for this patient?
A) Monotherapy with lisinopril
B) Initiation of two first-line antihypertensive
medications of different classes, such as a thiazide
diuretic and a calcium channel blocker
C) Monotherapy with metoprolol tartrate
D) Lifestyle interventions alone for another 6 months
Rationale: When initial blood pressure is >20/10
mmHg above goal (Stage 2 hypertension),
initiating a two-drug combination of different
,classes is recommended. For Black adults
without heart failure or CKD, thiazide diuretics
and calcium channel blockers are preferred
initial agents over ACE inhibitors.
Question 3
A 45-year-old female with a body mass index (BMI)
of 34 kg/m² and a history of non-alcoholic fatty liver
disease (NAFLD) presents to the clinic. Her HbA1c
is 5.9%, indicating prediabetes. Which of the
following interventions has shown the highest
efficacy in reducing progression to type 2 diabetes
and improving hepatic steatosis?
A) Monotherapy with sitagliptin
B) Intensive lifestyle modification targeting a 7% to
10% weight loss
C) Initiating low-dose acarbose
D) Initiating vitamin E supplementation alone
Rationale: Intensive lifestyle interventions
targeting weight loss of 7-10% are the gold
standard for treating prediabetes and NAFLD,
outperforming oral hypoglycemics in preventing
type 2 diabetes progression while reversing
hepatic fat accumulation.
Question 4
A 68-year-old male with a history of heart failure with
, reduced ejection fraction (HFrEF, EF 32%) presents
with stable class II New York Heart Association
(NYHA) symptoms. He is currently taking
sacubitril/valsartan, carvedilol, and empagliflozin. His
serum potassium is 4.1 mEq/L and eGFR is 55
mL/min/1.73m². Which medication should be added
next to optimize guideline-directed medical therapy
(GDMT)?
A) Isosorbide dinitrate
B) Digoxin
C) Spironolactone
D) Verapamil
Rationale: Mineralocorticoid receptor
antagonists (MRAs) like spironolactone are
recommended in patients with NYHA class II-IV
HFrEF who have adequate renal function and
potassium levels, as they significantly reduce
all-cause mortality and cardiovascular
hospitalizations.
Question 5
A 38-year-old female presents with persistent
fatigue, weight gain, and dry skin. Labs reveal a
Thyroid Stimulating Hormone (TSH) level of 12.4
mIU/L (Normal: 0.4–4.0) and a normal free T4 level.
She has a positive test for anti-thyroid peroxidase
REVIEW 2026 COMPREHENSIVE STUDY
GUIDE & PRACTICE TEST PACK
Master the 2026 Family Medicine Certification Examination with
this comprehensive, high-yield board review simulation optimized
for peak clinical performance. Each question features realistic
clinical vignettes spanning pediatric, geriatric, and chronic disease
management, meticulously formatted with italicized correct
answers and bold-italicized rationales for immediate self-grading.
This expert-curated test prep guide is the ultimate resource for
residents and physicians aiming to pass the ABFM and AAFP
board exams on their first attempt.
Section 1: Chronic Disease Management
Question 1
A 62-year-old man with type 2 diabetes mellitus,
hypertension, and stage 3a chronic kidney disease
(eGFR 48 mL/min/1.73m²) comes for follow-up. His
current medications include maximum-dose
metformin and lisinopril, but his HbA1c is 8.1%.
Aside from glycemic control, which class of
medication should be added to provide proven renal
and cardiovascular protective benefits?
A) Sulfonylurea
B) Dipeptidyl peptidase-4 (DPP-4) inhibitor
C) Sodium-glucose cotransporter-2 (SGLT2)
inhibitor
,D) Long-acting basal insulin
Rationale: SGLT2 inhibitors (such as
empagliflozin or dapagliflozin) have robust,
guideline-backed evidence demonstrating a
reduction in the progression of diabetic kidney
disease, cardiovascular events, and heart failure
hospitalizations, even in patients already
optimized on metformin.
Question 2
A 54-year-old African American woman with
essential hypertension presents with blood pressure
readings consistently averaging 152/94 mmHg over
three separate visits. She currently takes no
medications. According to current ACC/AHA
guidelines, what is the most appropriate initial
pharmacological treatment regimen for this patient?
A) Monotherapy with lisinopril
B) Initiation of two first-line antihypertensive
medications of different classes, such as a thiazide
diuretic and a calcium channel blocker
C) Monotherapy with metoprolol tartrate
D) Lifestyle interventions alone for another 6 months
Rationale: When initial blood pressure is >20/10
mmHg above goal (Stage 2 hypertension),
initiating a two-drug combination of different
,classes is recommended. For Black adults
without heart failure or CKD, thiazide diuretics
and calcium channel blockers are preferred
initial agents over ACE inhibitors.
Question 3
A 45-year-old female with a body mass index (BMI)
of 34 kg/m² and a history of non-alcoholic fatty liver
disease (NAFLD) presents to the clinic. Her HbA1c
is 5.9%, indicating prediabetes. Which of the
following interventions has shown the highest
efficacy in reducing progression to type 2 diabetes
and improving hepatic steatosis?
A) Monotherapy with sitagliptin
B) Intensive lifestyle modification targeting a 7% to
10% weight loss
C) Initiating low-dose acarbose
D) Initiating vitamin E supplementation alone
Rationale: Intensive lifestyle interventions
targeting weight loss of 7-10% are the gold
standard for treating prediabetes and NAFLD,
outperforming oral hypoglycemics in preventing
type 2 diabetes progression while reversing
hepatic fat accumulation.
Question 4
A 68-year-old male with a history of heart failure with
, reduced ejection fraction (HFrEF, EF 32%) presents
with stable class II New York Heart Association
(NYHA) symptoms. He is currently taking
sacubitril/valsartan, carvedilol, and empagliflozin. His
serum potassium is 4.1 mEq/L and eGFR is 55
mL/min/1.73m². Which medication should be added
next to optimize guideline-directed medical therapy
(GDMT)?
A) Isosorbide dinitrate
B) Digoxin
C) Spironolactone
D) Verapamil
Rationale: Mineralocorticoid receptor
antagonists (MRAs) like spironolactone are
recommended in patients with NYHA class II-IV
HFrEF who have adequate renal function and
potassium levels, as they significantly reduce
all-cause mortality and cardiovascular
hospitalizations.
Question 5
A 38-year-old female presents with persistent
fatigue, weight gain, and dry skin. Labs reveal a
Thyroid Stimulating Hormone (TSH) level of 12.4
mIU/L (Normal: 0.4–4.0) and a normal free T4 level.
She has a positive test for anti-thyroid peroxidase
